Patents Assigned to LIPOTEK PTY LTD.
  • Patent number: 10507236
    Abstract: The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalizing an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 17, 2019
    Assignees: Lipotek Pty Ltd, The Australian National University
    Inventors: Jason David Price, Christopher Parish, Ines Atmosukarto
  • Publication number: 20140341971
    Abstract: The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.
    Type: Application
    Filed: June 20, 2014
    Publication date: November 20, 2014
    Applicants: LIPOTEK PTY LTD, DOMANTIS LIMITED
    Inventors: Joseph ALTIN, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
  • Patent number: 8779107
    Abstract: The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: July 15, 2014
    Assignees: Lipotek Pty Ltd, Domantis Limited
    Inventors: Joseph Altin, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
  • Publication number: 20140079728
    Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 20, 2014
    Applicant: Lipotek Pty Ltd.
    Inventors: David C. Jackson, Christopher R. Parish
  • Publication number: 20130142864
    Abstract: The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.
    Type: Application
    Filed: December 28, 2012
    Publication date: June 6, 2013
    Applicant: Lipotek Pty Ltd.
    Inventors: Joseph Altin, Christopher Richard Parish
  • Publication number: 20110200632
    Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.
    Type: Application
    Filed: February 2, 2011
    Publication date: August 18, 2011
    Applicant: Lipotek Pty Ltd.
    Inventors: David C. Jackson, Christopher R. Parish
  • Publication number: 20080233143
    Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.
    Type: Application
    Filed: February 7, 2006
    Publication date: September 25, 2008
    Applicant: LIPOTEK PTY LTD.
    Inventors: David C. Jackson, Christopher Richard Parish
  • Publication number: 20070026057
    Abstract: The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.
    Type: Application
    Filed: August 23, 2004
    Publication date: February 1, 2007
    Applicant: LIPOTEK PTY LTD.
    Inventors: Joseph Altin, Christopher Parish